Industry Overview

LAMEA silent heart attack market was valued at $576.2 million in 2025 and is projected to reach $1054.7 million by 2035, growing at a CAGR of 6.3% from 2026 to 2035. Silent myocardial infarction represents a critical subset of cardiovascular disease in which symptoms are minimal or absent, often resulting in delayed diagnosis and a higher risk of severe complications. The market encompasses a wide range of diagnostic and treatment solutions, including electrocardiogram (ECG) systems, cardiac biomarker tests such as troponin and CK-MB, advanced cardiac imaging technologies, wearable and remote monitoring devices, as well as pharmacological therapies and interventional procedures. Market growth is primarily driven by the increasing prevalence of cardiovascular diseases, a rapidly aging population, and growing awareness regarding preventive healthcare across the LAMEA regions. Additionally, improving healthcare infrastructure and rising adoption of advanced diagnostic tools are enabling better detection and management of asymptomatic cardiac conditions.

Technological advancements are playing a pivotal role in enhancing early detection and treatment outcomes. In March 2026, iRhythm Technologies presented data at the ACC 2026, demonstrating that its Zio ambulatory ECG monitoring system can identify a high prevalence of clinically actionable arrhythmias across diverse patient populations. These findings highlight the growing importance of continuous cardiac monitoring in detecting asymptomatic cardiovascular conditions, including silent heart attacks. Furthermore, in August 2025, GE HealthCare introduced the Vivid Pioneer, an AI-powered cardiovascular ultrasound system designed to enhance imaging speed, accuracy, and diagnostic confidence. By integrating advanced 2D, 4D, and AI-driven imaging capabilities, the system improves the detection of subtle cardiac abnormalities that might otherwise go unnoticed. Collectively, these innovations are accelerating the adoption of advanced diagnostics and strengthening clinical capabilities, thereby improving patient outcomes across healthcare systems in LAMEA.

Market Dynamics

High-Sensitivity Troponin Testing Driving Early Cardiac Detection in LAMEA

Cardiac biomarker testing, particularly troponin and CK-MB, dominates the diagnostic segment due to its high accuracy in detecting myocardial injury, even in asymptomatic cases. High-sensitivity troponin assays are increasingly adopted across hospitals and diagnostic centers in countries such as Brazil, Saudi Arabia, and the UAE, where early cardiac diagnosis is a growing priority. In February 2025, Roche highlighted the expanding role of cardiac biomarkers in enabling timely and precise diagnosis of acute myocardial infarction and heart failure. Biomarker-based diagnostics enhance clinical decision-making by supporting standardized care pathways and faster intervention. These advancements significantly strengthen early identification of silent heart attacks and improve diagnostic capabilities across healthcare systems in LAMEA.

Advanced Interventional Technologies Strengthen Cardiac Treatment Outcomes in LAMEA

Interventional procedures dominate the treatment segment due to their effectiveness in restoring blood flow and preventing complications following diagnosis. Techniques such as angioplasty and stent placement are increasingly adopted across key LAMEA markets, including Brazil, the UAE, and Saudi Arabia, supported by rising investments in cardiac care infrastructure. In October 2025, Terumo received FDA 510(k) clearance for its OPUSWAVE dual sensor imaging system and DualView imaging catheter. The technology integrates OFDI and IVUS modalities, enabling comprehensive and high-resolution visualization of coronary arteries. This advancement enhances diagnostic precision and treatment planning, supporting early detection and effective management of silent heart attacks across healthcare systems in LAMEA.

Market Segmentation

• Based on diagnostic, the market is segmented into electrocardiogram (ECG), cardiac biomarker testing (troponin, CK-MB), cardiac imaging, and wearable & remote monitoring devices.
• Based on treatment type, the market is segmented into pharmacological treatment, interventional procedures, and lifestyle & preventive management.
• Based on end-user, the market is segmented into hospitals, cardiology clinics, diagnostic centers, and home care settings.

Increasing Adoption of Cardiac Biomarker Testing in LAMEA

Cardiac biomarker testing is gaining significant importance in the LAMEA silent heart attack market due to the growing burden of cardiovascular diseases and increasing demand for rapid and accurate diagnosis. Biomarkers such as troponin and CK-MB are widely used across hospitals and diagnostic laboratories for the early detection of silent myocardial infarction and cardiac tissue damage. The rising expansion of diagnostic laboratory networks, improving access to emergency healthcare services, and growing awareness regarding preventive cardiac screening are supporting segment growth across several countries in Latin America and the Middle East. In addition, healthcare providers are increasingly adopting high-sensitivity biomarker assays to improve diagnostic accuracy and reduce treatment delays. Government initiatives aimed at strengthening healthcare infrastructure and improving cardiovascular disease management are further contributing to the expansion of this segment in the LAMEA region.

Growing Demand for Interventional Procedures in LAMEA

Interventional procedures are witnessing increasing demand in the LAMEA silent heart attack market due to the rising incidence of coronary artery disease and growing availability of advanced cardiac treatment facilities. Procedures such as angioplasty, stent implantation, and catheter-based interventions are becoming more common across major hospitals and specialized cardiac centers in the region. Increasing investments in healthcare infrastructure modernization, and expansion of catheterization laboratories are supporting the adoption of minimally invasive cardiac procedures. In addition, the growing preference for faster recovery times, reduced hospitalization, and improved treatment outcomes is driving the demand for interventional cardiac care. The presence of international medical device manufacturers and improving access to advanced cardiac technologies are also strengthening the growth of this segment across LAMEA countries.

Regional Outlook

LAMEA silent heart attack market is further divided by countries, including Brazil, Argentina, Mexico, Saudi Arabia, UAE, Qatar, South Africa, Nigeria, and Other LAMEA.

Brazil is the leading country in the LAMEA Silent Heart Attack Market

Brazil stands out as the leading country in the LAMEA Silent Heart Attack Market, driven by its large population, significant cardiovascular disease burden, and a well-established public healthcare system supported by government initiatives. In April 2025, a study published in PubMed Central analyzed cardiovascular mortality trends in Brazil using Global Burden of Disease data. The findings indicated that cardiovascular diseases continue to be a major cause of death despite improvements in healthcare access and risk factor management. This persistent burden underscores the growing need for early and accurate detection of cardiac conditions. Consequently, the demand for advanced diagnostic technologies to identify asymptomatic conditions such as silent heart attacks is increasing across Brazil and the broader LAMEA region.

Market Players Outlook

The major companies operating in the LAMEA silent heart attack market include Abbott Laboratories, Medtronic, Siemens Healthineers, Danaher, and Philips Healthcare, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In February 2025, Nyxoah commercially launched its Genio® neurostimulation system in the Middle East, with the first implantation performed at Saudi German Hospital in Dubai, UAE. Although focused on obstructive sleep apnea, the expansion is significant for the LAMEA cardiovascular monitoring ecosystem because sleep apnea is strongly associated with increased risks of silent heart attacks, arrhythmias, and cardiovascular disease. The launch marked Nyxoah’s expansion into the Middle East and Africa region through advanced AI-enabled cardiac-related monitoring technologies.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the LAMEA silent heart attack market
• Based on the availability of data, information related to new Protections and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.